Phil Kantoff on AR-V7: Ready for use in daily clinical decision making

Phil Kantoff presented, "AR-V7- ready for use in daily clinical decision making?" a point/counterpoint discussion at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC)  in St. Gallen, Switzerland.  Neal Shore, MD, interview Dr. Kantoff regarding his Pro position on AR-V7 and the risk benefit of certain drugs and tests and the costs involved. 

Dr. Philip Kantoff is the Chairman of Medicine at Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College. He is also the incumbent George J. Bosl Chair in Medicine. Dr. Kantoff oversees the clinical care, translational and clinical research of almost 400 faculty members in the Department of Medicine. He ensures the mentorship of fellows and junior faculty and cares for patients with prostate cancer. Dr. Kantoff’s laboratory- based research is devoted principally to the genetics and genetic epidemiology of prostate cancer, resistance to androgen deprivation therapy and the discovery of new biomarkers as potential prognostic and therapeutic targets. He lectures widely on both his research and the care of patients with these malignancies. 

Neal Shore, MD 

Additional reading:
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Access to all Advanced Prostate Cancer Consensus Conference Video Coverage

Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer